代表性论著：

2024

1.Sun Q, Ouyang L. Boosting Med Chem Education: Integrating Biology for Drug Discovery Talents. J Med Chem. 2024. doi: 10.1021/acs.jmedchem.4c02208IF: 6.8 Q1 .

2.Ouyang L, Shuai W, Yang P, Xiao H, Zhu Y, Bu F, Wang A, Sun Q, Wang G. Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases. Angew Chem Int Ed Engl. 2024:e202411037. doi: 10.1002/anie.202411037IF: 16.1 Q1 . 

3.Feng G, Yang X, Shuai W, Wang G, Ouyang L. Update on JNK inhibitor patents: 2015 to present. Expert Opin Ther Pat. 2024:1-21. doi: 10.1080/13543776.2024.2400167IF: 5.4 Q1 . 

4.Yu B, Ouyang L. Journal of Medicinal Chemistry Collection: Drug Discovery in China. J Med Chem. 2024;67(17):14700-14701. doi: 10.1021/acs.jmedchem.4c01922IF: 6.8 Q1 . 

5.Feng G, Wu Y, Hu Y, Shuai W, Yang X, Li Y, Ouyang L, Wang G. Small molecule inhibitors targeting m6A regulators. J Hematol Oncol. 2024;17(1):30. doi: 10.1186/s13045-024-01546-5IF: 29.5 Q1 . 

6.Shuai W, Xiao H, Yang P, Zhang Y, Bu F, Wu Y, Sun Q, Wang G, Ouyang L. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors. J Med Chem. 2024;67(8):6425-6455. doi: 10.1021/acs.jmedchem.3c02392IF: 6.8 Q1 .

7.Wang A, Shuai W, Wu C, Pei J, Yang P, Wang X, Li S, Liu J, Wang Y, Wang G, Ouyang L. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFRL858R/T790M/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers. J Med Chem. 2024;67(4):2777-2801. doi: 10.1021/acs.jmedchem.3c01934IF: 6.8 Q1 . 

8.Liu J, Wu Y, Meng S, Xu P, Li S, Li Y, Hu X, Ouyang L, Wang G. Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives. Mol Cancer. 2024;23(1):22. doi: 10.1186/s12943-024-01934-yIF: 27.7 Q1 .

9.Li R, Wu Y, Li Y, Shuai W, Wang A, Zhu Y, Hu X, Xia Y, Ouyang L, Wang G. Targeted regulated cell death with small molecule compounds in colorectal cancer: Current perspectives of targeted therapy and molecular mechanisms. Eur J Med Chem. 2024;265:116040. doi: 10.1016/j.ejmech.2023.116040IF: 6.0 Q1 . 

11.《自噬与药物发现》（欧阳亮, 孙秋主编. 北京 : 科学出版社, 2024. 8）

2023

1.Wang J, Zhang J, Wang J, Hu X, Ouyang L*, Wang Y*. Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics. J Med Chem. 2023;66(10):6437-6462. doi: 10.1021/acs.jmedchem.2c01655IF: 6.8 Q1 B1

2.Li Y, Liu Y, Zhang D, Chen J, Yang G, Tang P, Yang C, Liu J, Zhang J, Ouyang L*. Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy. J Med Chem. 2023;66(17):12069-12100. doi: 10.1021/acs.jmedchem.3c00640IF: 6.8 Q1 B1. 

3.Zhang L, Zhen Y, Feng L, Li Z, Lu Y, Wang G, Ouyang L*. Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer. Eur J Med Chem. 2023;259:115648. doi: 10.1016/j.ejmech.2023.115648IF: 6.0 Q1 B2. 

4.Tang W, Lin C, Yu Q, Zhang D, Liu Y, Zhang L, Zhou Z, Zhang J, Ouyang L*. Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery. J Med Chem. 2023;66(11):7140-7161. doi: 10.1021/acs.jmedchem.3c00566IF: 6.8 Q1 B1. 

5.Pei J, Wang G, Wang A, Wu C, Pan X, Shuai W, Bu F, Zhu Y, Wang Y, Ouyang L*, Li W. Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell 6.Lung Cancer. J Med Chem. 2023;66(8):5719-5752. doi: 10.1021/acs.jmedchem.3c00027IF: 6.8 Q1 B1.

6.Wang G, Wu Y, Wu C, Shuai W, Jiang T, Wang A, Bu F, Sun Q, Ouyang L*. Rational design and crystallographic analysis of novel isoform-selective TRKA inhibitors for cancer therapy. Acta Pharm Sin B. 2023;13(1):440-443. doi: 10.1016/j.apsb.2022.10.012IF: 14.7 Q1 B1. 

7.Tan L, Wu C, Zhang J, Yu Q, Wang X, Zhang L, Ge M, Wang Z, Ouyang L*, Wang Y*. Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site. J Med Chem. 2023;66(5):3588-3620. doi: 10.1021/acs.jmedchem.2c02115IF: 6.8 Q1 B1 .

8.Shuai W, Bu F, Zhu Y, Wu Y, Xiao H, Pan X, Zhang J, Sun Q, Wang G, Ouyang L*. Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2023;66(2):1273-1300. doi: 10.1021/acs.jmedchem.2c01410IF: 6.8 Q1 B1. 

2022

9.Feng L, Wang G, Chen Y, He G, Liu B, Liu J, Chiang CM, Ouyang L*. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Med Res Rev. 2022;42(2):710-743. doi: 10.1002/med.21859IF: 10.9 Q1 B1. 

10.Lin C, Chen Y, Zhu M, Pei J, Zhou Y, Gou M, Ouyang L*. A sulfhydryl blocking reagent BT-4 sensitizes cisplatin-based micelle prodrugs for efficient treatment of breast cancer. Int J Pharm. 2022;626:122187. doi: 10.1016/j.ijpharm.2022.122187. 

11.Zhan P, Yu B, Ouyang L*. Drug repurposing: An effective strategy to accelerate contemporary drug discovery. Drug Discov Today. 2022;27(7):1785-1788. doi: 10.1016/j.drudis.2022.05.026. 

12.Pan X, Pei J, Wang A, Shuai W, Feng L, Bu F, Zhu Y, Zhang L, Wang G, Ouyang L*. Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy. Acta Pharm Sin B. 2022;12(5):2171-2192. doi: 10.1016/j.apsb.2021.12.022IF: 14.7 Q1 B1. 

13.Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L*. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy. J Med Chem. 2022;65(9):6803-6825. doi: 10.1021/acs.jmedchem.2c00135IF: 6.8 Q1 B1. 

14.Chen J, Tang P, Wang Y, Wang J, Yang C, Li Y, Yang G, Wu F, Zhang J, Ouyang L*. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. J Med Chem. 2022;65(7):5184-5211. doi: 10.1021/acs.jmedchem.1c01835IF: 6.8 Q1 B1. 

15.Tan L, Zhang J, Wang Y, Wang X, Wang Y, Zhang Z, Shuai W, Wang G, Chen J, Wang C, Ouyang L*, Li W. Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. J Med Chem. 2022;65(7):5149-5183. doi: 10.1021/acs.jmedchem.1c01714IF: 6.8 Q1 B1. 

16.Zhu Y, Shuai W, Zhao M, Pan X, Pei J, Wu Y, Bu F, Wang A, Ouyang L*, Wang G*. Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases. J Med Chem. 2022;65(5):3758-3775. doi: 10.1021/acs.jmedchem.1c01947. 

17.Bu F, Zhang J, Shuai W, Liu J, Sun Q, Ouyang L*. Repurposing drugs in autophagy for the treatment of cancer: From bench to bedside. Drug Discov Today. 2022;27(7):1815-1831. doi: 10.1016/j.drudis.2021.11.013IF: 6.5 Q1 B2. 

2021

18.Zhang J, Tang P, Zou L, Zhang J, Chen J, Yang C, He G, Liu B, Liu J, Chiang CM, Wang G, Ye T, Ouyang L*. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. J Med Chem. 2021;64(24):18025-18053. doi: 10.1021/acs.jmedchem.1c01382IF: 6.8 Q1 B1. 

19.Zhang L, Zhang L, Guo Y, Xiao M, Feng L, Yang C, Wang G, Ouyang L*. MCDB: A comprehensive curated mitotic catastrophe database for retrieval, protein sequence alignment, and target prediction. Acta Pharm Sin B. 2021;11(10):3092-3104. doi: 10.1016/j.apsb.2021.05.032. 

20.Lin C, Gao H, Ouyang L*. Advance cardiac nanomedicine by targeting the pathophysiological characteristics of heart failure. J Control Release. 2021;337:494-504. doi: 10.1016/j.jconrel.2021.08.002IF: 10.5 Q1 B1. 

21.Xu T, Zhang J, Yang C, Pluta R, Wang G, Ye T, Ouyang L*. Identification and optimization of 3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer. Eur J Med Chem. 2021;219:113424. doi: 10.1016/j.ejmech.2021.113424IF: 6.0 Q1 B2. 

22.Li Y, Yang G, Yang C, Tang P, Chen J, Zhang J, Liu J, Ouyang L*. Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery. J Med Chem. 2021;64(16):11798-11815. doi: 10.1021/acs.jmedchem.1c00579IF: 6.8 Q1 B1. 

23.Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L*. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem. 2021;64(16):12022-12048. doi: 10.1021/acs.jmedchem.1c00678. 

24.Tang P, Zhang J, Liu J, Chiang CM, Ouyang L*. Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. J Med Chem. 2021;64(5):2419-2435. doi: 10.1021/acs.jmedchem.0c01487. 

25.Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L*, Liu B*. Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. J Med Chem. 2021;64(5):2382-2418. doi: 10.1021/acs.jmedchem.0c01180IF: 6.8 Q1 B1. 

26.Pei J, Pan X, Wang A, Shuai W, Bu F, Tang P, Zhang S, Zhang Y, Wang G, Ouyang L*. Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy. Chem Commun (Camb). 2021;57(97):13194-13197. doi: 10.1039/d1cc04661fIF: 4.3 Q2 B2. 

27.Pei J, Wang G, Feng L, Zhang J, Jiang T, Sun Q, Ouyang L*. Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery. J Med Chem. 2021 Apr 8;64(7):3493-3507. doi: 10.1021/acs.jmedchem.0c01689. 

28.Yang C, Zhang J, Liao M, Yang Y, Wang Y, Yuan Y, Ouyang L*. Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy. Drug Discov Today. 2021;26(3):817-825. doi: 10.1016/j.drudis.2020.12.006. 

29.Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y, Ouyang L*. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm Sin B. 2021;11(2):355-372. doi: 10.1016/j.apsb.2020.05.004IF: 14.7 Q1 B1. 

30.Chang X, Sun D, Shi D, Wang G, Chen Y, Zhang K, Tan H, Liu J, Liu B, Ouyang L*. Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy. Acta Pharm Sin B. 2021;11(1):156-180. doi: 10.1016/j.apsb.2020.06.003. 

2020

31.Chen Y, Wang G, Ouyang L*. Promising inhibitors targeting Mpro: an ideal strategy for anti-SARS-CoV-2 drug discovery. Signal Transduct Target Ther. 2020;5(1):173. doi: 10.1038/s41392-020-00291-8IF: 40.8 Q1 B1. 

32.Wang G, Zhao Y, Liu Y, Sun D, Zhen Y, Liu J, Fu L, Zhang L, Ouyang L*. Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types. J Med Chem. 2020;63(8):3976-3995. doi: 10.1021/acs.jmedchem.9b01896IF: 6.8 Q1 B1. 

33.Xiang H, Zhang J, Lin C, Zhang L, Liu B, Ouyang L*. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm Sin B. 2020;10(4):569-581. doi: 10.1016/j.apsb.2019.10.003IF: 14.7 Q1 B1.  

【代表性专利（第一发明人）】

1、CN202111046514.7.

2、CN202110617650.0.

3、CN202010039345.3.

4、CN202010877378.5.

5、CN108218814A.

6、CN107987054A.

7、CN107903185A.

8、CN106905347B.

9、CN106748892B.

10、CN106478550B.

11、CN106117176B.

12、PCT/CN2018/072575